Evidence map›Paper›PMID 37176074›Full record

ArticleInternational journal of molecular sciences2023

Investigating Chemokine-Matrix Networks in Breast Cancer: Tenascin-C Sets the Tone for CCL2.

Martha Gschwandtner, Anís N Gammage, Claire Deligne, Linda F M Mies, Alissa Domaingo, Devardarssen Murdamoothoo, Thomas Loustau, Anja Schwenzer, Rupert Derler, Raphael Carapito and 5 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 5 countries.

Martha GschwandtnerKennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK.ORCID 0000-0001-8869-5924
Anís N GammageKennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK.ORCID 0000-0002-7493-8988
Claire DeligneKennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK.
Linda F M MiesKennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK.
Alissa DomaingoInstitute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.
Devardarssen MurdamoothooINSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, 67091 Strasbourg, France.
Thomas LoustauINSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, 67091 Strasbourg, France.ORCID 0000-0003-4662-5228
Anja SchwenzerKennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK.ORCID 0000-0001-6375-924X
Rupert DerlerInstitute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.
Raphael CarapitoFédération de Médecine Translationnelle de Strasbourg (FMTS), 67091 Strasbourg, France.ORCID 0000-0002-7036-442X
Manuel KochInstitute for Dental Research and Oral, Musculoskeletal Research, Center for Biochemistry, University of Cologne, 50931 Cologne, Germany.ORCID 0000-0002-2962-7814
Matthias MörgelinColzyx AB, Medicon Village, Scheeletorget 1, 223 63 Lund, Sweden.
Gertraud OrendINSERM U1109-MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy, 67091 Strasbourg, France.ORCID 0000-0003-2522-1195
Andreas J KunglInstitute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.ORCID 0000-0003-3362-797X
Kim S MidwoodKennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK.
University of Oxford · GBInserm · FRUniversity of Graz · ATMedicon Village · SEUniversity of Cologne · DE

Funding

Worldwide Cancer Research 14-1070
6 · The paper itself

Abstract

Bidirectional dialogue between cellular and non-cellular components of the tumor microenvironment (TME) drives cancer survival. In the extracellular space, combinations of matrix molecules and soluble mediators provide external cues that dictate the behavior of TME resident cells. Often studied in isolation, integrated cues from complex tissue microenvironments likely function more cohesively. Here, we study the interplay between the matrix molecule tenascin-C (TNC) and chemokine CCL2, both elevated in and associated with the progression of breast cancer and playing key roles in myeloid immune responses. We uncover a correlation between TNC/CCL2 tissue levels in HER2+ breast cancer and examine the physical and functional interactions of these molecules in a murine disease model with tunable TNC levels and in in vitro cellular and cell-free models. TNC supported sustained CCL2 synthesis, with chemokine binding to TNC via two distinct domains. TNC dominated the behavior of tumor-resident myeloid cells; CCL2 did not impact macrophage survival/activation whilst TNC facilitated an immune suppressive macrophage phenotype that was not dependent on or altered by CCL2 co-expression. Together, these data map new binding partners within the TME and demonstrate that whilst the matrix exerts transcriptional control over the chemokine, each plays a distinct role in subverting anti-tumoral immunity.

Indexed as

NeoplasmsTenascinAnimalsChemokine CCL2ChemokinesExtracellular MatrixMacrophagesMiceSignal TransductionChemokine CCL2ChemokinesTenascinbreast cancerCCL2extracellular matrixmacrophagesMCP-1myeloid cellstenascin-C

Identifiers

PMID37176074
PMCPMC10179296
OpenAlexW4376630515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.